Literature DB >> 12920221

Expression of the ets-1 proto-oncogene in melanocytic lesions.

Connie A Keehn1, Bruce R Smoller, Michael B Morgan.   

Abstract

Ets-1 oncoprotein is a transcription factor known to regulate the expression of numerous genes important in extracellular matrix remodeling and angiogenesis. Up-regulation of Ets-1 has been shown to be important in a variety of human malignancies and to correlate with prognosis. To our knowledge, this oncoprotein has not been examined in melanocytic lesions. A series of 10 cutaneous melanomas and 24 benign melanocytic lesions with patient records were independently examined for diagnosis confirmation and immunohistochemical expression by two dermatopathologists. The immunohistochemical expression for Ets-1 (Novocastra, Newcastle upon Tyne, UK) was scored by an average of the mean labeling intensity; no nuclear staining = 0, weak nuclear staining = 1, moderate = 2, and intense = 3. Ets-1 expression was statistically assessed by the one-way analysis of variance (ANOVA) comparing the mean labeling intensity of melanoma to benign melanocytic nevi. All of the benign melanocytic lesions exhibited negative to weak nuclear staining, with an average mean labeling intensity of 0.4. Melanoma in situ exhibited moderate nuclear staining, for a mean labeling intensity of 2.0, whereas all conventional invasive melanomas exhibited moderate to strong nuclear staining, with a mean labeling intensity of 2.7. Metastatic melanoma exhibited very strong nuclear staining, with a mean labeling intensity of 3.0. Invasive desmoplastic melanoma, like melanoma in situ, showed moderate nuclear staining with a mean labeling intensity of 2.1. There was a trend toward more intense staining with melanoma progression. A statistically significant difference in the mean labeling intensity of Ets-1 was seen between invasive melanoma and benign melanocytic nevi (P <.0001). Ets-1 oncoprotein expression, however, does not distinguish among benign melanocytic lesions. Staining intensity and pattern might be a useful adjunct with histomorphology in distinguishing invasive melanoma from benign melanocytic nevi. Furthermore, Ets-1 expression may be an important pathogenic mechanism and predictor of aggressive biologic behavior of cutaneous melanoma, with a trend toward staining intensity increasing as Clark stage increases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920221     DOI: 10.1097/01.MP.0000082395.59356.4F

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification.

Authors:  Rohit Mehra; Saravana M Dhanasekaran; Nallasivam Palanisamy; Pankaj Vats; Xuhong Cao; Jung H Kim; David Sl Kim; Timothy Johnson; Douglas R Fullen; Arul M Chinnaiyan
Journal:  Transl Oncol       Date:  2013-08-01       Impact factor: 4.243

2.  The transcription factors Ets1 and Sox10 interact during murine melanocyte development.

Authors:  Amy Saldana-Caboverde; Erasmo M Perera; Dawn E Watkins-Chow; Nancy F Hansen; Meghana Vemulapalli; James C Mullikin; William J Pavan; Lidia Kos
Journal:  Dev Biol       Date:  2015-04-23       Impact factor: 3.582

3.  Targeting Pan-ETS Factors Inhibits Melanoma Progression.

Authors:  Lee Huang; Yougang Zhai; Jennifer La; Jason W Lui; Stephen P G Moore; Elizabeth C Little; Sixia Xiao; Adil J Haresi; Candice Brem; Jag Bhawan; Deborah Lang
Journal:  Cancer Res       Date:  2021-02-01       Impact factor: 13.312

4.  ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression.

Authors:  Jaskaren S Kohli; Hira Mir; Afsheen Wasif; Heung Chong; Victoria Akhras; Rajiv Kumar; Eduardo Nagore; Dorothy C Bennett
Journal:  Oncotarget       Date:  2017-11-01

5.  ETS-1 and ETS-2 are upregulated in a transgenic mouse model of pigmented ocular neoplasm.

Authors:  G De la Houssaye; V Vieira; C Masson; F Beermann; J L Dufier; M Menasche; M Abitbol
Journal:  Mol Vis       Date:  2008-10-29       Impact factor: 2.367

6.  PAX3 and ETS1 synergistically activate MET expression in melanoma cells.

Authors:  J D Kubic; E C Little; J W Lui; T Iizuka; D Lang
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

7.  SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.

Authors:  Shira Ashkenazi; Rona Ortenberg; Michal Besser; Jacob Schachter; Gal Markel
Journal:  Oncotarget       Date:  2016-05-24

8.  Inhibiting cell migration and cell invasion by silencing the transcription factor ETS-1 in human bladder cancer.

Authors:  Li Liu; Yuchen Liu; Xintao Zhang; Mingwei Chen; Hanwei Wu; Muqi Lin; Yonghao Zhan; Chengle Zhuang; Junhao Lin; Jianfa Li; Wen Xu; Xing Fu; Qiaoxia Zhang; Xiaojuan Sun; Guoping Zhao; Weiren Huang
Journal:  Oncotarget       Date:  2016-05-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.